logo

For the Inventor, By the Inventor

Charenton-le-Pont, France

Vincent Mikol

USPTO Granted Patents = 21 

 

 

Average Co-Inventor Count = 7.0

ph-index = 7

Forward Citations = 194(Granted Patents)


Location History:

  • Paris, FR (2012 - 2013)
  • Charenton-le-Point, FR (2016)
  • Charenton-le-Pont, FR (2013 - 2022)

Company Filing History:

goldMedal20 out of 1,454 
 
Sanofi
 patents
silverMedal1 out of 1 
 
Sanof Aventis
 patent

Years Active: 2012-2022

Loading Chart...
Loading Chart...
Loading Chart...
21 patents (USPTO):Explore Patents
1. 11453727 - Antibodies that bind IL-4 and/or IL-13 and their uses (2022-09-27),
2. 10759871 - Antibodies that bind IL-4 and/or IL-13 and their uses (2020-09-01),
3. 10112991 - Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide (2018-10-30),
4. 9815902 - Humanized anti-CXCR5 antibodies, derivatives thereof and their uses (2017-11-14),
5. 9738728 - Antibodies that bind IL-4 and/or IL-13 and their uses (2017-08-22),
6. 9732162 - Antibodies that bind IL-4 and/or IL-13 and their uses (2017-08-15),
7. 9676864 - Antibodies that specifically bind to the EphA2 receptor (2017-06-13),
8. 9441040 - Antagonist antibodies and their fab fragments against GPVI and uses thereof (2016-09-13),
9. 9382312 - Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide (2016-07-05),
10. 9243067 - Humanized anti-CXCR5 antibodies, derivatives thereof and their use (2016-01-26),
11. 9228019 - Humanized anti-CXCR5 antibodies, derivatives thereof and their use (2016-01-05),
12. 9221917 - Dual variable region antibody-like binding proteins having cross-over binding region orientation (2015-12-29),
13. 9181349 - Dual variable region antibody-like binding proteins having cross-over binding region orientation (2015-11-10),
14. 9175087 - Humanized anti-CXCR5 antibodies, derivatives thereof and their use (2015-11-03),
15. 8980262 - Humanized anti-CXCR5 antibodies, derivatives thereof and their use (2015-03-17),

Title: **Vincent Mikol: Innovator in Biopharmaceuticals**

Introduction

Vincent Mikol, located in Charenton-le-Pont, France, is an accomplished inventor with a remarkable portfolio of 21 patents. His work primarily focuses on developing innovative therapies targeting IL-4 and IL-13, which are critical in the treatment of various allergic diseases.

Latest Patents

Among his latest patents, Vincent Mikol has made significant contributions with his inventions concerning antibodies that bind IL-4 and/or IL-13. These novel humanized anti-IL-4 and IL-13 antibodies, along with fragments and bispecific antibodies, hold the potential to revolutionize the treatment of IL-4 and IL-13 mediated diseases. Notably, his work aims to address conditions such as allergic asthma and dermatitis, showcasing his dedication to advancing biopharmaceutical therapies.

Career Highlights

Vincent has had a distinguished career, notably working with renowned companies such as Sanofi and Sanofi Aventis. His experience in these organizations has allowed him to develop and refine his expertise in antibody engineering and therapeutic innovation, contributing significantly to the field of immunology.

Collaborations

Throughout his career, Vincent Mikol has collaborated with talented professionals, including Beatrice Cameron and Ercole Rao. These partnerships have facilitated impactful research and the advancement of novel therapeutic solutions in treating complex diseases.

Conclusion

Vincent Mikol stands out as a leading inventor in the biopharmaceutical sector. His continued efforts in developing innovative therapies for IL-4 and IL-13 mediated diseases position him as a key player in the field of immunological research. The potential of his inventions promises to enhance treatment options and improve the quality of life for individuals suffering from allergic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…